Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and MACCEs in Patients with Diabetic Foot Ulcers: An Ambispective Longitudinal Cohort Study

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2024 Mar 11

PMID 38465347

Authors

Xiuxian Huang

Zhengming Li

Zhenwei Zhai

Qiu Wang

Rongyan Wei

Jiacheng Mo

Jianhao Huang

Wensheng Lu

Affiliations

Soon will be listed here.

Abstract

Aim: Metabolic dysfunction-related fatty liver disease (MAFLD) is closely related to metabolic disorders. However, the relationship between MAFLD and the prognosis in diabetic foot ulcers (DFUs) remains unclear. This study aimed to explore the association between MAFLD and the risk of major adverse cardiac and cerebral events (MACCEs) in patients with DFUs.

Methods: 889 inpatients with DFUs (PEDIS/TEXAS mild and above) were included in this study from 2013 to 2023. All participants were placed into non-MAFLD ( = 643) and MAFLD ( = 246) groups and followed up every 6 months for 10.9 years with a median of 63 months through in-person outpatient interviews and family fixed-line telephone visits. The association between MAFLD and the risk of MACCEs was evaluated through Multivariate Cox regression analyses, Stratified analyses and Kaplan-Meier survival analyses.

Results: Of the 889 subjects, 214 (24.07%) experienced MACCEs. Multivariate Cox regression analysis showed that MAFLD was independently associated with MACCEs ( < 0.001), of which with non-fatal myocardial infarction ( = 0.04), non-fatal stroke ( = 0.047), coronary artery revascularization ( = 0.002), heart failure (P = 0.029), and all-cause mortality ( = 0.021), respectively. The stratified analysis revealed that compared with non-MAFLD (HR=1), DFUs with MAFLD had a 2.64-fold increased risk for MACCEs (P <0.001; for interaction = 0.001) in peripheral arterial disease (PAD) subgroup. Kaplan-Meier analysis evidenced that the MAFLD group had a higher cumulative incidence of MACCEs (log-rank, all < 0.05).

Conclusion: MAFLD is a high-risk factor for MACCEs in patients with DFUs. The findings will remind clinicians to pay more attention to MAFLD in patients with DFUs, especially in patients with DFUs combined with PAD as early as possible in clinical practice and adopt timely effective intervention strategies to prevent the occurrence of MACCEs to improve the clinical prognosis in patients with DFUs.

Citing Articles

From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status.

Boccatonda A, DArdes D, Moronti V, Santilli J, Cipollone A, Lessiani G Medicina (Kaunas). 2024; 60(11).

PMID: 39596967 PMC: 11596241. DOI: 10.3390/medicina60111781.

Red cell distribution width/albumin ratio as a marker for metabolic syndrome: findings from a cross-sectional study.

Guo H, Wang Y, Miao Y, Lin Q BMC Endocr Disord. 2024; 24(1):227.

PMID: 39455980 PMC: 11515435. DOI: 10.1186/s12902-024-01762-7.

References

Armstrong D, Boulton A, Bus S . Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017; 376(24):2367-2375. DOI: 10.1056/NEJMra1615439. View

Shimabukuro M . MAFLD and ASCVD: Plasma Heparin Cofactor II Activity as an Anti-liver Fibrosis Biomarker. J Atheroscler Thromb. 2023; 30(8):853-854. PMC: 10406663. DOI: 10.5551/jat.ED227. View

Samuel V, Shulman G . The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016; 126(1):12-22. PMC: 4701542. DOI: 10.1172/JCI77812. View

Abenavoli L, Scarlata G, Scarpellini E, Boccuto L, Spagnuolo R, Tilocca B . Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome. Medicina (Kaunas). 2023; 59(3). PMC: 10054528. DOI: 10.3390/medicina59030594. View

Walsh J, Hoffstad O, O Sullivan M, Margolis D . Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med. 2015; 33(11):1493-1498. DOI: 10.1111/dme.13054. View

Cholongitas E, Tsilingiris D, Diamantopoulou P, Mastrogianni E, Tentolouris A, Karagiannakis D . Association of cardiovascular factors in diabetic patients with non-alcoholic fatty liver disease. Hormones (Athens). 2021; 21(1):133-145. DOI: 10.1007/s42000-021-00334-x. View

Armstrong D, Swerdlow M, Armstrong A, Conte M, Padula W, Bus S . Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020; 13(1):16. PMC: 7092527. DOI: 10.1186/s13047-020-00383-2. View

Meyersohn N, Mayrhofer T, Corey K, Bittner D, Staziaki P, Szilveszter B . Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clin Gastroenterol Hepatol. 2020; 19(7):1480-1488.e14. PMC: 7855524. DOI: 10.1016/j.cgh.2020.07.030. View

Awasthi A, Corrie L, Vishwas S, Gulati M, Kumar B, Chellappan D . Gut Dysbiosis and Diabetic Foot Ulcer: Role of Probiotics. Pharmaceutics. 2022; 14(11). PMC: 9699533. DOI: 10.3390/pharmaceutics14112543. View

10.

Eslam M, El-Serag H, Francque S, Sarin S, Wei L, Bugianesi E . Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022; 19(10):638-651. DOI: 10.1038/s41575-022-00635-5. View

11.

Targher G, Lonardo A, Byrne C . Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2017; 14(2):99-114. DOI: 10.1038/nrendo.2017.173. View

12.

Tang M, Wei X, Cao H, Zhen Q, Liu F, Wang Y . Association between Chinese visceral adiposity index and metabolic-associated fatty liver disease in Chinese adults with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022; 13:935980. PMC: 9376620. DOI: 10.3389/fendo.2022.935980. View

13.

Le M, Yeo Y, Li X, Li J, Zou B, Wu Y . 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021; 20(12):2809-2817.e28. DOI: 10.1016/j.cgh.2021.12.002. View

14.

Jeeyavudeen M, Khan S, Fouda S, Pappachan J . Management of metabolic-associated fatty liver disease: The diabetology perspective. World J Gastroenterol. 2023; 29(1):126-143. PMC: 9850951. DOI: 10.3748/wjg.v29.i1.126. View

15.

Alexander M, Loomis A, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D . Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019; 367:l5367. PMC: 6780322. DOI: 10.1136/bmj.l5367. View

16.

Jeon B, Choi H, Kang J, Tak M, Park E . Comparison of five systems of classification of diabetic foot ulcers and predictive factors for amputation. Int Wound J. 2016; 14(3):537-545. PMC: 7949506. DOI: 10.1111/iwj.12642. View

17.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

18.

Guan C, Fu S, Zhen D, Yang K, An J, Wang Y . Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center. J Diabetes Res. 2022; 2022:8429847. PMC: 8816602. DOI: 10.1155/2022/8429847. View

19.

Vita T, Murphy D, Osborne M, Bajaj N, Keraliya A, Jacob S . Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. Radiology. 2019; 291(2):330-337. PMC: 6492883. DOI: 10.1148/radiol.2019181793. View

20.

Fan J, Farrell G . Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2008; 50(1):204-10. DOI: 10.1016/j.jhep.2008.10.010. View